Mer­ck, Pfiz­er line up a big FDA de­ci­sion on a block­buster hope­ful, star­ing down some ma­jor league com­pe­ti­tion

Two Big Phar­ma col­lab­o­ra­tors — Mer­ck and Pfiz­er — have moved their SGLT2 di­a­betes drug hope­ful er­tugliflozin in­to the hands of reg­u­la­tors on both sides of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA